Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rIL-29 + Ribavirin in Chronic HCV
NCT01001754Phase 2Unknown
- Sponsor
- ZymoGenetics
- Start
- May 2010
- Primary completion
- Nov 2010
- Modality
- Cytokines & Interferons
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of peginterferon lambda-1a in hepatitis C (HCV) (3 arms), sponsored by ZymoGenetics. Primary endpoints: Hepatitis C Virus RNA Level at 48 weeks and Incidence and Severity of Adverse Events at 48 weeks. Status: unknown.
02
Drugs
peginterferon lambda-1a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01001754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001754.